 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...4567891011121314...178179» |
- irinotecan / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Molecular landscape and site of metastasis in PDAC. (Hall A; Poster Bd #: 139) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3888;
When comparing pancreatic LM to OM sites, our data reinforces the observation that OS is better in OM vs LM and response to ICI was better in OM vs. LM. Significant differences were observed in molecular landscape, TME and signatures that are predictive of immunotherapy response (TIS and IFG scores).
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Post-progression therapies and outcomes for patients with advanced, BRCA-related pancreatic cancer after receipt of PARP inhibitors: A national retrospective cohort study. (Hall A; Poster Bd #: 136) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3886;
Further work will be needed to identify mechanisms of resistance to PARPi and to optimize post-progression treatments. This work adds to a growing body of literature supporting an individualized approach to post-progression therapy decisions for these patients.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg., pirfenidone / Generic mfg.
Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer. (Hall A; Poster Bd #: 132) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3882;
This work adds to a growing body of literature supporting an individualized approach to post-progression therapy decisions for these patients. Adding PFD to AG showed promising ORR and DCR and an acceptable adverse event in patients with metastatic pancreatic cancer.
- albumin-bound paclitaxel / Generic mfg.
GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS. (Hall A; Poster Bd #: 130) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3880;
P
We did not find an association with tumor location, which also was not prognostic in this study. Importantly GATA6 was predictive of survival in patients receiving mFFX, suggesting GATA6 low tumors should receive 1 st line GnP based regimens.
- nadunolimab (CAN04) / Cantargia
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data. (Hall A; Poster Bd #: 128) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3878;
P1/2
The phase I/IIa CANFOUR trial of nadunolimab in combination with nab-paclitaxel and gemcitabine (GN) in previously untreated, unresectable, locally advanced or metastatic PDAC, showed promising efficacy with median OS: 13.2 months; median iPFS: 7.2 months; 1-year survival: 58% and iORR: 33%, with a good safety profile...In mice, vincristine and nab-paclitaxel caused long-lasting (2 weeks) CIPN. Data from PDAC patients receiving nadunolimab + GN and experiments in preclinical models suggest that targeting IL1RAP by nadunolimab may combine antitumor activity with potent reduction of CIPN.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC). (Hall A; Poster Bd #: 126) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3876;
P2
The results of the phase II study have shown that YH003 plus Toripalimab with/without chemotherapy, as 1L or 2L treatment in patients with u/m PDAC have promising antitumor activity and response durability, especially in the Caucasian subgroups. Both treatment regimens are well tolerated.
- Opdivo (nivolumab) / BMS
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer. (Hall A; Poster Bd #: 123) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3873;
P1/2
The interim analysis suggests that the combination of CM24/nivo/Nal-IRI/5FU/LV has a manageable safety profile with a longer PFS supported by higher ORR and DCR. OS Data continues to mature and will be reported once available.
- FG-M108 / FutureGen Biopharmaceutical
FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study. (Hall A; Poster Bd #: 122) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3872;
P1
FG-M108 plus AG showed excellent safety profile and promising clinical efficacy as 1L treatment for patients with CLDN18.2+ locally advanced unresectable or metastatic PC. The safety and efficacy, especially PFS and OS, of FG-M108 plus AG treatment will be further evaluated.
- irinotecan liposomal / CSPC Pharma
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer. (Hall A; Poster Bd #: 121) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3871;
P2
The safety and efficacy, especially PFS and OS, of FG-M108 plus AG treatment will be further evaluated. Patients with unresectable locally advanced or metastatic pancreatic cancer were randomly assigned (2:1) to receive NALIRIFOX (HE072 50 mg/m
- defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205). (Hall A; Poster Bd #: 120) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3870;
P1/2
No DLTs were reported across the 4 dosing cohorts/schedules and safety signals were consistent with previous clinical data. Updated safety and efficacy will be reported.
- Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase 1 study of anti (Hall A; Poster Bd #: 119) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3869;
P1
The 4-drug combination showed increased clinical efficacy compared with that historically observed for chemotherapy regimens. Further evaluation is needed to confirm the clinical activities observed.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma. (Hall A; Poster Bd #: 117) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3867;
P1
Cohort B treatment, which included hydroxychloroquine, incurred more early discontinuations. As designed, neither cohort will advance to Stage 2, highlighting the need for further tailored therapeutic approaches in mPDAC.
- albumin-bound paclitaxel / Generic mfg.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-na (Hall A; Poster Bd #: 116) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3866;
P3
In this 29-month follow-up of NAPOLI 3, NALIRIFOX continued to demonstrate improved OS compared with Gem+NabP, with 11 patients still receiving the NALIRIFOX regimen. These data confirm NALIRIFOX as a new possible standard of care and reference regimen for the first-line treatment of patients with mPDAC.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study. (Hall A; Poster Bd #: 115) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3865;
P2
PAAG regimen as first-line treatment was demonstrated to be tolerable, with promising anti-tumor activity in mPC. The identified biomolecular markers revealed potential to guide precision treatment of PAAG for mPC.
- albumin-bound paclitaxel / Generic mfg.
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer. (Hall A; Poster Bd #: 84) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3835;
P
GemCis/nab-P showed promising survival outcomes in advanced BTC. Further, patients with TP53 mutations or high tumoral levels of VSIG4, ITGA3, and CCL8 showed a poor prognosis after GemCis/nab-P treatment.
- albumin-bound paclitaxel / Generic mfg.
Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial. (Hall A; Poster Bd #: 67) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3818;
P2
The results meet our initial aim that preoperative chemotherapy with albumin-bound paclitaxel, cisplatin and capecitabine is highly active and resulted in a considerable pCR and MPR rate with promising 3-year survival rate in pts with locally advanced ESCC, while well-tolerated. This triplet regimen could be another effective neoadjuvant treatment strategy for locally advanced ESCC.
- Tevimbra (tislelizumab-jsgr) / BeiGene
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial. (Hall A; Poster Bd #: 58) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3809;
P2
In addition, some hub genes were found to be associated with non-MPR after neoadjuvant therapy. Further experimental studies are needed to investigate these findings.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study. (Hall A; Poster Bd #: 55) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3806;
P
In this phase 2 study, patients (pts) with histopathologically confirmed ESCC, diagnosed as clinical stage cT1-3N1-3M0 and ECOG PS 0-1 were enrolled to receive two cycles of neoadjuvant chemoimmunotherapy with PD-1 blockade (Pembrolizumab/Tislelizumab on d1) plus nab-paclitaxel (260mg/m 2 in total on d1 and d8) and cisplatin (60mg/m 2 in total on d1-3) of each 21-day cycle, followed by esophagectomy. Combining PD-1 blockade with nab-paclitaxel and cisplatin is feasible and effective in patients with locally advanced resectable ESCC, and might be a promising approach for neoadjuvant treatment.
- albumin-bound paclitaxel / Generic mfg.
Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study. (Hall A; Poster Bd #: 37) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3790;
P2
Nab-paclitaxel 150mg/m2 (starting on D2,23) and cisplatin, 75mg/m2(starting on D2-4,22-24) were administered for two cycles. Concurrent chemoradiotherapy and immunotherapy yielded satisfactory 1-year OS rate and manageable toxicities in oligometastatic recurrence patients with ESCC after radical surgery.
- Tyvyt (sintilimab) / Eli Lilly
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA). (Hall A; Poster Bd #: 17) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3771;
P2
EPHB1 mutation and dynamic change of TCR could serve as potential predictive factors. Further investigation is warranted.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma. (Hall A; Poster Bd #: 406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3540;
Mean cell diameter of tumor, derived from OGSE sequences, emerges as a potential new radiomic marker for predicting NAIC efficacy. Ongoing follow-ups on long-term survival and the development of a bio-radiomic prediction model integrating pathological features with OGSE data are underway.
- Keytruda (pembrolizumab) / Merck (MSD)
Analysis of PD-L1 expression in locally advanced head and neck squamous cell carcinoma and its correlation with the efficacy of neoadjuvant immunotherapy + chemotherapy: A retrospective real-world study. (Hall A; Poster Bd #: 390) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3525;
The oral cavity is the most common primary in HNSCC in Hunan,China. In the locally advanced , the proportion of PD-L1 CPS ?20 is higher than reported in other studies.
- Tevimbra (tislelizumab-jsgr) / BeiGene
Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial. (Hall A; Poster Bd #: 386) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3521;
The 1-year EFS and OS compared favorably with historical data. These encouraging results warrant further investigations.
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma. (Hall A; Poster Bd #: 361) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3496;
Compared with regular treatment, tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy was feasible and well tolerated in LA-NPC patients. This trial is supportive of further prospective trials in LA-NPC.
- nanoencapsulated paclitaxel (FID-007) / ANP Technologies, Fulgent Genetics
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma. (Hall A; Poster Bd #: 345) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3493;
P1
FID demonstrates preliminary evidence of anti-tumor activity in heavily pre-treated HNSCC pts across different primary tumor sites, with an ORR 56%, including those with prior taxane exposure. A phase 2 study of FID with cetuximab in pts with HNSCC is planned to begin enrollment in 2024.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study. (Hall A; Poster Bd #: 326) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3474;
P2
Pembrolizumab combined with nab-paclitaxel and platinum shows encouraging antitumor activity accompanied by a manageable safety profile in untreated R/M HNSCC patients in China. CDKN2A mutation was a potential independent prognostic factors for this patient population.
- A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B. (Hall A; Poster Bd #: 373) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3367;
Platinum plus anthracycline showed better response rates than other platinum combinations as a first-line chemotherapy, but there was no significant difference in PFS and OS. The median PFS for primary treatment was about one year, whereas the overall survival was nearly ten years, indicating the need for long-term multidisciplinary approach.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche
A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab (Hall A; Poster Bd #: 327) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3323;
P2
The Ki value derived from dynamic total-body FDG PET/CT proved instrumental in guiding the addition of bevacizumab to neoadjuvant therapy. Both cohorts exhibited promising responses to neoadjuvant therapy, suggesting that neoadjuvant chemotherapy plus tislelizumab
- Tevimbra (tislelizumab-jsgr) / BeiGene
The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer. (Hall A; Poster Bd #: 320) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3316;
Patients received 3 to 4 cycles (Q3W) of chemoimmunotherapy including carboplatin (area under the curve [AUC] 5mg/mL/min), nab-paclitaxel (squamous NSCLC, 260mg/m 2 ) or pemetrexed (non-squamous NSCLC, 500mg/m 2 ), and tislelizumab(200mg). The findings of this study indicate encouraging antitumor activity and manageable safety of induction chemoimmunotherapy, and the response-adapted strategy requires further exploration in locally advanced unresctable non-small cell lung cancer.
- Keytruda (pembrolizumab) / Merck (MSD)
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ?50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L). (Hall A; Poster Bd #: 312) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3309;
P2
Higher PD-L1 TPS cases achieved higher RR, including some CRs and higher 2-year PFS rate. To confirm our hypothesis that RT-free P+C can be a less toxic curative option in selected LA-NSCLC pts with PD-L1 TPS ?50%, further data is warranted.
- Tevimbra (tislelizumab-jsgr) / BeiGene
A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC). (Hall A; Poster Bd #: 286) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3283;
Patients (pts) with stage IIIA/IIIB EGFR/ALK/ROS wild-type NSCLC received 2 cycles of neoadjuvantchemoimmunotherapy (PD-1 inhibitor TIS, nab-paclitaxel, and cisplatin/carboplatin) and were reassessed for surgery.Thereafter, pts underwent surgery within 6 weeks and continued 2 cycles of TIS plus chemotherapy, followed by up to 15 cycles of TIS monotherapy. Neoadjuvant TIS plus chemotherapy increased surgical opportunities and survival benefits in potentially resectable locally advanced stage IIIA/IIIB NSCLC.
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer. (Hall A; Poster Bd #: 88) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3010;
P2
Concurrent exposure to antibiotics, and specifically fluoroquinolones during ICI therapy was associated with a statistically significant improvement in OS in patients with metastatic CRC, but not metastatic pancreatic cancer. This is discrepant from prior reports in other tumor types and suggests that the gut microbiome may impact ICI efficacy uniquely in patient with CRC.
- albumin-bound paclitaxel / Generic mfg.
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial. (Hall A; Poster Bd #: 279a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2901;
P2
four weeks of paclitaxel or nab-paclitaxel weekly or biweekly planned, as standard of care and at treating physician's discretion; willing to adhere to requirement that no new pain medication or dose changes be taken throughout the first 12 weeks of the study period; and willing to adhere to all study-related procedures...With 80 patients we will have 80% power to detect a difference between arms as small as 10 points on the NPS, assuming a one-sided test, type I error of 5%, correlation between baseline and follow-up measurements of 0.5, SD of 17, and 15% attrition at week 4. Present accrual and target accrual: We accrued 43 participants in the intervention phase by the end of January 2024; the target accrual is 80 participants.
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors. (Hall A; Poster Bd #: 184) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2591;
CHIP is common in patients with solid tumors. Although not appearing to impact rates of AEs, CHIP may impact outcomes from Chemo or IO.
- Tevimbra (tislelizumab-jsgr) / BeiGene
Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study. (Hall A; Poster Bd #: 450) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2226;
Stage IV penile squamous cell carcinoma treated with chemotherapy combined with Tislelizumab has a high objective response rate and controllable adverse reactions, A high proportion of patients with regional lymph node metastases had the opportunity to regain surgery or radiotherapy. It is expected to change the poor effect of chemotherapy alone for stage IV squamous cell carcinoma of penis.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety. (Hall A; Poster Bd #: 428) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1871;
Updated results reconfirm a favorable antitumor activity and manageable safety from anlotinib plus albumin-bound paclitaxel in the treatment of recurrent ovarian or peritoneal carcinoma. Further survival results are expected.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant chemo-immunotherapy following concurrent immuno-chemoradiotherapy and immune-maintenance therapy as primary treatment for locally advanced cervical cancer: A prospective, single-arm, phase 2 trial. (Hall A; Poster Bd #: 404) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1847;
The interim data support Camrelizumab plus TP neoadjuvant chemo-immunotherapy following immuno-chemoradiotherapy and Camrelizumab maintenance therapy as an active go-forward regimen in LACC. No new safety signals were observed, and most AEs were mild to moderate.
- Tecentriq (atezolizumab) / Roche
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan. (Hall A; Poster Bd #: 437) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1448;
P
median had poorer efficacy and safety outcomes. 1.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase II study of combination of radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer: North Japan Lung Cancer Study Group 1902. (Hall A; Poster Bd #: 405) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1417;
1. Pts received 4 cycles of cisplatin or carboplatin plus pemetrexed or (nab-) paclitaxel plus pembro, followed by pembro
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS). (Hall A; Poster Bd #: 188) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1324;
P2
Pts received 4 cycles of cisplatin or carboplatin plus pemetrexed or (nab-) paclitaxel plus pembro, followed by pembro Patients aged 18 to 70 years old with previously untreated stage II
- Opdivo (nivolumab) / BMS, vusolimogene oderparepvec (RP1) / Replimune
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician's choice in patients with advanced melanoma that has progressed on anti (Hall A; Poster Bd #: 385b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_909;
P3
Patients aged 18 to 70 years old with previously untreated stage II The combination of anti
- Fruzaqla (fruquintinib) / Takeda
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study. (Hall A; Poster Bd #: 454) - Apr 24, 2024 - Abstract #ASCO2024ASCO_736;
P
Fruquintinib demonstrated as an potential option for patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs, with satisfactory efficacy and safety profile when used in combination therapy. More prospective trials on fruquintinib are needed, especially on different pathological types and diverse combination regimens.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov) - Apr 24, 2024
P2, N=59, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
More prospective trials on fruquintinib are needed, especially on different pathological types and diverse combination regimens. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jan 2024
- || Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Enrollment closed, Metastases: Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 24, 2024
P2, N=60, Active, not recruiting, Sponsor: Salspera LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jan 2024 Recruiting --> Active, not recruiting
- | carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., pirfenidone / Generic mfg.
Retrospective data, Journal, Combination therapy: A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis. (Pubmed Central) - Apr 23, 2024
George's Respiratory Questionnaire score and the recurrence rate of ICIP, but there was no significant difference between the 2 groups (P?>?.05). Adding pirfenidone to glucocorticoid treatment was shown to be safe and may be more beneficial than glucocorticoids alone for improving pulmonary interstitial lesions, reversing ICIP, and preventing its recurrence.
- | Tyvyt (sintilimab) / Eli Lilly
New trial, Metastases, Immune cell: the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer (clinicaltrials.gov) - Apr 23, 2024
P=N/A, N=20, Recruiting, Sponsor: RenJi Hospital
- ||| AMG 193 / Amgen
Enrollment open, Combination therapy, Metastases: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Apr 22, 2024
P1, N=282, Recruiting, Sponsor: Amgen
Adding pirfenidone to glucocorticoid treatment was shown to be safe and may be more beneficial than glucocorticoids alone for improving pulmonary interstitial lesions, reversing ICIP, and preventing its recurrence. Not yet recruiting --> Recruiting
- | Sulanda (surufatinib) / Hutchmed
New trial, Metastases: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 22, 2024
P=N/A, N=72, Completed, Sponsor: Luo Cong
- || Imfinzi (durvalumab) / AstraZeneca, abequolixron (RGX-104) / Inspirna
Enrollment open, Combination therapy: Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov) - Apr 22, 2024
P1, N=24, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD)
The tumor immune environment in advanced breast cancer following treatment with pembrolizumab and nab-paclitaxel (Exhibit Hall F1; Poster Board Number: B965) - Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2621;
The final results will determine intrinsic subtype signatures of each cohort and study crosstalk between different cell types in the TME. In conclusion, our approach aims to enhance the understanding of treatment response and TME's role in metastatic breast cancer for improved therapeutic strategies.